SCHEMBL3535210

SCHEMBL3535210

CCOC(=O)C(Cl)Oc1ccc([N+](=O)[O-])cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.56
CRHBP P24387 1/20 0.56
CRHR2 Q13324 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.55
KDM4E B2RXH2 3/20 0.49
LMNA P02545 2/20 0.49
HTR2A P28223 1/20 0.49
BCL9 O00512 1/20 0.49
CTNNB1 P35222 1/20 0.49
KMT2A Q03164 3/20 0.48
ALDH1A1 P00352 4/20 0.47
GAA P10253 2/20 0.47
MEN1 O00255 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
RAB9A P51151 2/20 0.46
NPC1 O15118 1/20 0.46
HTT P42858 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
BCHE P06276 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15516165 0.85 MAPT (0.59) MAPTCRHBPCRHR2L3MBTL1KDM4E
SCHEMBL655938 0.84 MAPT (0.58) MAPTCRHBPCRHR2L3MBTL1KDM4E
SCHEMBL11421535 0.83 MAPT (0.65) MAPTCRHBPCRHR2L3MBTL1KDM4E
SCHEMBL30098369 0.82 MAPT (0.56) MAPTCRHBPCRHR2L3MBTL1KDM4E
SCHEMBL11708706 0.82 MAPT (0.56) MAPTCRHBPCRHR2L3MBTL1KDM4E
SCHEMBL8949976 0.80 MAPT (0.54) MAPTCRHBPCRHR2L3MBTL1KDM4E
SCHEMBL11786127 0.80 MAPT (0.54) MAPTCRHBPCRHR2L3MBTL1KDM4E
SCHEMBL6391326 0.80 MAPT (0.57) MAPTCRHBPCRHR2L3MBTL1KDM4E
SCHEMBL11727131 0.80 PPARA (0.51) MAPTL3MBTL1LMNAHTR2AKMT2A
SCHEMBL9722713 0.80 ALDH1A1 (0.50) MAPTLMNAHTR2ABCL9CTNNB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7816385-B2 Dimeric dicarboxylic acid derivatives, their preparation and use HIGH POINT PHARMACEUTICALS, LLC (US) 2010-10-19 US disclosed
EP-1578716-A1 DICARBOXYLIC ACID DERIVATIVES AS PPAR-AGONISTS NOVO NORDISK A/S (DK) 2005-09-28 EP disclosed
US-20040259950-A1 Novel compounds, their preparation and use HIGH POINT PHARMACEUTICALS, LLC 2004-12-23 US disclosed
WO-2004056740-A1 DICARBOXYLIC ACID DERIVATIVES AS PPAR-AGONISTS NOVO NORDISK A/S (DK) 2004-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259950-A1 Novel compounds, their preparation and use PPARG, PPARA, PPARD MAPT 3047/4885CRHBP 2584/4885CRHR2 2384/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.